All In Biotech

Drug Trial Radar · NCT05624554

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Mar 16, 2023

Primary completion

May 19, 2027

Study completion Mar 17, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • NemtabrutinibDrug

    65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.

  • FludarabineDrug

    25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.

  • CyclophosphamideDrug

    250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.

  • BendamustineDrug

    Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.

  • RituximabBiological

    Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.

  • TruximaBiological

    Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.

  • RuxienceBiological

    Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.

  • RiabniBiological

    Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 49 months

Locations

97 sites in 21 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group ( Site 5205)

    Springdale, Arkansas

  • Clermont Oncology Center ( Site 5224)

    Clermont, Florida

  • Hattiesburg Clinic Hematology/Oncology ( Site 5216)

    Hattiesburg, Mississippi

  • Medical Oncology Associates, PS ( Site 5206)

    Spokane, Washington

  • Royal Adelaide Hospital ( Site 1105)

    Adelaide, South Australia, Australia

  • Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1319)

    Rio de Janeiro, Brazil

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308)

    São Paulo, Brazil

  • Hospital Paulistano-Americas Oncologia ( Site 1302)

    São Paulo, Brazil

  • Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1317)

    Curitiba, Paraná, Brazil

  • Hospital Amaral Carvalho-Centro de Pesquisas ( Site 1304)

    Jaú, São Paulo, Brazil

  • A. C. Camargo Cancer Center ( Site 1318)

    São Paulo, São Paulo, Brazil

  • University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD ( Site 6404)

    Plovdiv, Bulgaria

  • Medical Centre Pratia Clinic EOOD ( Site 6406)

    Plovdiv, Bulgaria

  • UMHAT "Prof. Dr. Stoyan Kirkovich"AD-Clinical Hematology ( Site 6400)

    Stara Zagora, Bulgaria

  • Multriprofile Hospital for Active Treatment "Hristo Botev" ( Site 6402)

    Vratsa, Bulgaria

  • Specialized Hospital for Active Treatment of Haematology Diseases ( Site 6403)

    Sofia, Sofia (stolitsa), Bulgaria

  • James Lind Centro de Investigacion del Cancer ( Site 1503)

    Temuco, Araucania, Chile

  • Biocenter ( Site 1507)

    Concepción, Biobio, Chile

  • IC La Serena Research ( Site 1506)

    La Serena, Coquimbo Region, Chile

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509)

    Santiago, Region M. de Santiago, Chile

  • FALP-UIDO ( Site 1500)

    Santiago, Region M. de Santiago, Chile

  • Clínica Inmunocel ( Site 1511)

    Santiago, Region M. de Santiago, Chile

  • Peking University Third Hospital ( Site 1602)

    Beijing, Beijing Municipality, China

  • Chongqing University Cancer Hospital ( Site 1605)

    Chongqing, Chongqing Municipality, China

  • Chongqing University Three Gorges Hospital ( Site 1609)

    Chongqing, Chongqing Municipality, China

  • Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 1607)

    Guangzhou, Guangdong, China

  • Sun Yat-sen University Cancer Center ( Site 1608)

    Guangzhou, Guangdong, China

  • The Affiliated Hospital of Guizhou Medical University ( Site 1625)

    Guiyang, Guizhou, China

  • Hainan General Hospital ( Site 1603)

    Haikou, Hainan, China

  • Henan Cancer Hospital-hematology department ( Site 1613)

    Zhengzhou, Henan, China

  • Tongji Hospital Tongji Medical,Science & Technology ( Site 1619)

    Wuhan, Hubei, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1618)

    Wuhan, Hubei, China

  • Xiangya Hospital Central South University-Hematology department ( Site 1616)

    Changsha, Hunan, China

  • Hunan Cancer Hospital ( Site 1615)

    Changsha, Hunan, China

  • The First Affiliated Hospital of Soochow University-hematology department ( Site 1612)

    Suzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University ( Site 1614)

    Nanchang, Jiangxi, China

  • Jiangxi Provincial Cancer Hospital ( Site 1628)

    Nanchang, Jiangxi, China

  • The First Hospital of Jilin University-Hematology ( Site 1621)

    Changchun, Jilin, China

  • The First Affiliated Hospital of Xi'an Jiaotong University ( Site 1617)

    Xi'an, Shaanxi, China

  • Shaanxi provincial people's hospital ( Site 1626)

    Xi'an, Shaanxi, China

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.